[go: up one dir, main page]

WO2016004093A3 - Therapeutic compositions including galectin-3 inhibitors and uses thereof - Google Patents

Therapeutic compositions including galectin-3 inhibitors and uses thereof Download PDF

Info

Publication number
WO2016004093A3
WO2016004093A3 PCT/US2015/038645 US2015038645W WO2016004093A3 WO 2016004093 A3 WO2016004093 A3 WO 2016004093A3 US 2015038645 W US2015038645 W US 2015038645W WO 2016004093 A3 WO2016004093 A3 WO 2016004093A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
phe
lys
arg
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/038645
Other languages
French (fr)
Other versions
WO2016004093A2 (en
Inventor
D. Travis Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Corp
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of WO2016004093A2 publication Critical patent/WO2016004093A2/en
Publication of WO2016004093A3 publication Critical patent/WO2016004093A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of galectin-3 inhibitors, and/or naturally or artificially occurring derivatives, variants, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to galectin-3 inhibitors and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/038645 2014-07-01 2015-06-30 Therapeutic compositions including galectin-3 inhibitors and uses thereof Ceased WO2016004093A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019535P 2014-07-01 2014-07-01
US62/019,535 2014-07-01

Publications (2)

Publication Number Publication Date
WO2016004093A2 WO2016004093A2 (en) 2016-01-07
WO2016004093A3 true WO2016004093A3 (en) 2016-03-03

Family

ID=55020090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/038645 Ceased WO2016004093A2 (en) 2014-07-01 2015-06-30 Therapeutic compositions including galectin-3 inhibitors and uses thereof

Country Status (1)

Country Link
WO (1) WO2016004093A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102236829B1 (en) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 Hepcidin analogues and uses therof
KR20170028307A (en) 2014-05-16 2017-03-13 프로타고니스트 테라퓨틱스, 인코포레이티드 47 47 integrin thioether peptide antagonists
SG11201700327WA (en) 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN110914287A (en) 2017-04-05 2020-03-24 隐形生物治疗公司 Crystalline salt form of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2
JP7368856B2 (en) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Cancer treatment by blocking the interaction between TIM-3 and its ligand
EP3661502A4 (en) 2017-08-03 2020-12-02 Galectin Sciences, LLC Compounds for the prevention and treatment of medical disorders and uses thereof
EP3681900A4 (en) * 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3466975A1 (en) * 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN112672765A (en) * 2018-06-29 2021-04-16 格莱科斯生物医药公司 Conjugates
JPWO2020096002A1 (en) * 2018-11-08 2021-12-09 国立大学法人 香川大学 Brown adipose / beige adipocyte activator containing D-allulose as an active ingredient
KR20210124308A (en) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. Anti-GAL3 antibodies and uses thereof
MX2022000397A (en) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
US20210100832A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
CN112745372B (en) * 2019-10-31 2022-07-12 深圳先进技术研究院 Functional saccharide molecule based on TDG molecular skeleton and preparation method thereof
KR20220112261A (en) * 2019-12-06 2022-08-10 트루바인딩 아이엔씨. Antibodies that block the interaction of GAL3 with insulin receptors or integrins and methods of using the same
US20230038373A1 (en) * 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
JP2023510866A (en) * 2020-01-13 2023-03-15 トゥルーバインディング，インコーポレイテッド Anti-GAL3 antibody and method of use
TW202515892A (en) 2020-01-15 2025-04-16 美商健生生物科技公司 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3174646A1 (en) * 2020-04-07 2021-10-14 Pieter Muntendam Methods and compositions for preventing and treating retinal nerve damage
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CA3173952A1 (en) * 2020-06-22 2021-12-30 Stealth Biotherapeutics Inc. Prodrugs of mitochondria-targeting oligopeptides
US20230227499A1 (en) * 2020-06-22 2023-07-20 Stealth Biotherapeutics Inc. Prodrugs of mitochondria-targeting oligopeptides
KR20230110570A (en) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. Compositions of Peptide Inhibitors of the Interleukin-23 Receptor
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Lipidated peptide inhibitors of interleukin-23 receptor
WO2023023256A1 (en) * 2021-08-18 2023-02-23 Oculogenex Inc. Aav-mediated gene transfer for retinopathy
CN118524852A (en) * 2021-11-09 2024-08-20 真和制药有限公司 Methods of treating or inhibiting cardiovascular disease
US20240352131A1 (en) * 2023-04-18 2024-10-24 Truebinding, Inc. Methods of treating eye disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610841B1 (en) * 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
WO2005001023A2 (en) * 2003-05-01 2005-01-06 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20070134279A1 (en) * 2005-12-09 2007-06-14 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
US20100311664A1 (en) * 2004-01-23 2010-12-09 Szeto Hazel H Methods for reducing oxidative damage
US20130244957A1 (en) * 2003-02-04 2013-09-19 Hazel H. Szeto Methods for preventing or treating mitochondrial permeability transition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610841B1 (en) * 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US20130244957A1 (en) * 2003-02-04 2013-09-19 Hazel H. Szeto Methods for preventing or treating mitochondrial permeability transition
WO2005001023A2 (en) * 2003-05-01 2005-01-06 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20100311664A1 (en) * 2004-01-23 2010-12-09 Szeto Hazel H Methods for reducing oxidative damage
US20070134279A1 (en) * 2005-12-09 2007-06-14 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
WO2016004093A2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
HK1215934A1 (en) Peptide therapeutics and methods for using same
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
HK1198869A1 (en) Combination treatments for hepatitis c
HK1249011A1 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
ZA201606320B (en) Human plasma kallikrein inhibitors
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
CY1119007T1 (en) COMPOSITIONS AND METHODS OF Pulmonary Hypertension Treatment
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
UA107550C2 (en) ESTRA-1,3,5 (10), 16-TETRAEIN-3-CARBOXAMAMID DERIVATIVES, THE METHODS OF THEIR PREPARATION, THE PHARMACEUTICAL PREPARATIONS THEREOF, AND THEIR USE
WO2012030160A3 (en) Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
MX2021010297A (en) Human plasma kallikrein inhibitors.
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
MX2022013450A (en) Pharmaceutical formulations.
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
NZ719321A (en) Storage stable lyophilized tripeptide formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15814758

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 15814758

Country of ref document: EP

Kind code of ref document: A2